We previously wrote about Genentech’s U.S. Patent No. 6,407,213 (“the ’213 patent”) to Carter, first in October 2017, and more...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Celltrion
-
-
In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a host of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
As we previously reported here and here, Celltrion filed suit against Genentech seeking declaratory judgment that a number of patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]